Search results
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 16 hours agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Motley Fool via Yahoo Finance· 2 days agoAfter falling by over 32% in the past 12 months, the pharma titan's shares are trading at a mere...
Donald Trump Flubs His Doctor's Name In Major Gaffe As He Questions Joe Biden's Mental Acuity
TheBlast via Yahoo News· 4 days agoThis election, however, is a choice. pic.twitter.com/8KssiJuJwQ — Joe Biden (@JoeBiden) June 14,...
3 Stocks to Sell as Ozempic Surges in Popularity
InvestorPlace via Yahoo Finance· 6 days agoNovo Nordisk’s (NYSE:NVO) Ozempic diabetes treatment, marketed as a weight loss treatment under the Wegovy brand name, has become the latest...
Biotech startup raises $190 million to focus on new approach to heart attack, stroke and more - San...
The Business Journals· 2 days agoA serial biotech entrepreneur, a longtime UCSF researcher, a shelved Big Pharma drug and $190...
Chutes & Ladders—Longtime J&J exec retiring after 17 years
FierceBiotech· 6 days agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...
10 Reasons to Buy Eli Lilly Stock Now
247wallst.com· 6 days agoThe pharmaceutical sector is one that has gone from decades of heavy investment, high growth, and consolidation to a maturing space with a few key...
Dissolving Big Pharma's Illusion of 'Safety'
Mercola· 4 days agoIn that book, Humphries details how vaccine science has been misrepresented to portray them as safe and effective, when in reality they’re neither. Humphries first became aware that vaccines ...
CNBC's Inside India newsletter: IPO boom looks to break new records
CNBC· 7 days agoInvestors wanting to cash in on India's growth have typically focused on storied conglomerates –...
Gateway - Quartz
Quartz· 2 days agoAlthough biosimilars will sell at a list price lower than Humira, there is no guarantee that patients will actually be offered as much access to cheaper biosimilars as they are to the
